GSK-2256098
Tier C — Watch / tradeGSK-2256098
Targets：FAK
Indications (approved)：Adenocarcinoma, Pancreatic cancer, Meningioma, Pulmonary hypertension, Solid tumour
Regional status
Synthetic routes & intermediates1 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| GSK-2256098-001 | 796851-03-1 | 2,5-dichloro-4-iodopyridine |
| GSK-2256098-002 | 1885-29-6 | 2-aminobenzonitrile |
| GSK-2256098-003 | 1224887-80-2 | 2-((2,5-dichloropyridin-4-yl)amino)benzonitrile |
| GSK-2256098-004 | 1124-16-9 | 1-isopropyl-3-methyl-1H-pyrazol-5-amine |
| GSK-2256098-005 | 1224887-82-4 | 2-((5-chloro-2-((1-isopropyl-3-methyl-1H-pyrazol-5-yl)amino)pyridin-4-yl)amino)benzonitrile |
| GSK-2256098-006 | 1224887-83-5 | 2-((5-chloro-2-((1-isopropyl-3-methyl-1H-pyrazol-5-yl)amino)pyridin-4-yl)amino)benzoic acid |
Frequently asked questions
What are the approved indications of GSK-2256098?
Approved indications include: Adenocarcinoma, Pancreatic cancer, Meningioma, Pulmonary hypertension, Solid tumour.
When does the GSK-2256098 patent expire?
No public expiry year is available for GSK-2256098 yet; this page updates once verified.
How many synthesis routes are recorded for GSK-2256098?
1 synthesis routes are recorded; the shortest is 4 steps with 74 g total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy GSK-2256098 intermediates?
All intermediates in GSK-2256098 routes have CAS profiles — you can submit an RFQ per CAS and it enters the Unibest matching pool.
How do I get a quote for GSK-2256098 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-11